The African Pharmaceutical Market is projected to grow at an impressive CAGR of 6-8% by 2029, driven by a booming population, ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The FDA placed a clinical hold on BioNTech’s Phase 1/2a trial for its investigational RNA-based malaria vaccine, BNT165e. BioNTech paused the study and is working with the FDA to address its ...

The US Food and Drug Administration has put a clinical hold on BioNTech’s investigational new drug (IND) application and Phase I/II clinical trial examining the company’s pipeline malaria vaccine.

Investing.com -- Shares of BioNTech SE (NASDAQ: NASDAQ: BNTX) fell 3% following news that the U.S. Food and Drug Administration (FDA) placed a clinical hold on the company’s Investigational New Drug ...

The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for malaria prevention.

Editor Louis Juricic Stock Markets Editor Louis Juricic Published03/04/2025, 04:36 PM BioNTech stock falls after FDA clinical hold on malaria vaccine trial View all comments (0)0 BNTX 5.51% ...

BioNTech’s BNT165e vaccine is part of its broader effort to expand its mRNA technology platform beyond the success of its COVID-19 vaccine, developed in partnership with Pfizer (NYSE: PFE).

Berlin: BioNTech has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on Friday.

BioNTech, a company founded by Turkish German immigrants that is famed for its COVID-19 vaccine, announced on Friday that it has started clinical trials for a malaria vaccine.

BioNTech’s planned vaccine production site in Kigali, Rwanda will help produce the malaria shot, Sahin said. BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.